No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
No Data
Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 15,746 Shares
Insider Sale at Mineralys Therapeutics Inc (MLYS): CFO and Secretary Adam Levy Sells Shares
Mineralys Therapeutics Price Target Announced at $30.00/Share by HC Wainwright & Co.
Mineralys Therapeutics Analyst Ratings
H.C. Wainwright Initiates Mineralys Therapeutics(MLYS.US) With Buy Rating, Announces Target Price $30
Buy Rating Justified by Mineralys Therapeutics' Promising Hypertension and CKD Drug Lorundrostat